Wednesday, May 20, 2026

Bedrocan flower to be offered as Becanex PIEX raw extract for compounding

The cannabis flower Bedrocan, widely prescribed in Germany, is expected to become available to pharmacies for the first time as a raw extract for extemporaneous compounding. The project is based on a long-term partnership between Dutch cannabis producer Bedrocan and Berlin-based extraction specialist Becanex. Shipments are slated to start in summer 2026.

First product planned: PIEX Bedrocan 70% THC

The first jointly developed product is planned as Becanex PIEX Bedrocan 70%, a THC raw extract. According to the companies, the extract is designed to retain a recognizable fingerprint of the original Bedrocan flower’s cannabinoid and terpene profile. Becanex says its proprietary extraction approach is intended to support predictable and consistent outcomes.

Use in multiple pharmacy preparations

The partners position the raw extract for incorporation into a range of patient-specific preparations, including:

• oral solutions
• capsules
• suppositories
• topical dosage forms
• inhalation preparations

Vaporization is highlighted as an additional inhalation option alongside the flower format.

How the partners describe the collaboration

Bedrocan and Becanex frame the partnership around applying the same expectations of care, standardization and transparency to medical cannabis as to other pharmaceutical active substances. In a statement, Bedrocan CEO Jaap Erkelens points to the fit between Bedrocan’s cultivation expertise and Becanex’s extraction capabilities, and to the potential for prescribers to use Bedrocan in compounded preparations.

“We have always been precise in how we cultivate our cannabis. Becanex is equally precise in how it is extracted. This shared attention to detail is exactly what makes this product worth presenting to pharmacies, prescribers and patients. In addition, the raw extract enables physicians to prescribe our core product Bedrocan in a variety of compounded preparations.”

Becanex director Sebastian Kamphorst says the teams had already produced early extracts from Bedrocan flower under a scientific licence in 2014, but that a suitable regulatory framework was missing at the time. The current effort is intended to bring that work to market readiness.

“Patients who have found a cannabis variety that works for them should not have to compromise when they need it in a different form. With Bedrocan as a partner, we can now enable prescribers to do exactly that, based on a variety they already trust. The fact that we are here today is no coincidence: back in 2014, the team around Becanex co-founder Eral Osmanoglou developed initial extracts from Bedrocan flower together with Bedrocan under a scientific licence. Back then, the regulatory framework for such a product was missing, today we are returning to those results and bringing them to market readiness.”

Germany named as first launch market

According to the companies, Germany will be the first market for the introduction. The partners also plan to present their joint products at two industry events, Cannabis Europe in London and the Medical Cannabis Congress in Berlin, scheduled to take place in the same week.